Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

NCT02490176 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether a medication called glucagon-like peptide-1 affects heart function in people with heart failure, measured by changes in blood flow using a device called PiCCO.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 50 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2015-07 · est. completion 2016-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02490176 ↗

Description as written by the study sponsor.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.

Treatments tested

liraglutide Drug

Liraglutide were taken daily for 7 days
placebo Drug

Placebo were taken daily for 7 days

Main thing measured	a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology
Sponsor	Chinese PLA General Hospital
Conditions studied	Heart Failure
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02490176 ↗